It was a real honour to hear from doctor Roger Jelliffe this month: if we talk about IATDMCT heroes, he would be closer to a super hero status. Dr Jelliffe shares his extraordinary career in modelling drug behaviour, and its use for dose adaptation and personalization of therapy, mixing in ideas along the way from nuclear science, aerospace engineering and astronomy.

Roger Jelliffe
Consultant Clinical Pharmacologist, Laboratory of Applied Pharmacokinetics and Bioinformatics
University of Southern California, Keck School of Medicine
Los Angeles, CA, USA

Many thanks to the Compass Editorial Team:

Paula Schaiquevich
Edgar Spencer
Franck Saint-Marcoux.

I really enjoyed the June 2016 Compass. Have you read it yet?

I thought I would briefly overview the reports as a reminder of this fantastic space we have for sharing amongst our members. The Compass is a member only benefit, so we recommend sharing the news with your colleagues who might not be members.  You could forward this blog post, or the monthly E-News, or boldly send them an IATDMCT membership application form!

This month Ofelia Noceti, active IATDMCT member and collaborator with the Immuosuppressive Drugs Committee and its Biomarkers Working Group, shares her experiences as a clinical pharmacologist in liver transplant and disease, and the challenges of implementing biomarker research findings in clinical practice.

Ofelia Noceti
National Center for Liver Transplantation and Liver Diseases
Hospital Central de las Fuerzas Armadas
Montevideo, Uruguay

At the IATDMCT Stuttgart congress in 2011, Professor Pierre Marquet entered as the new President and presented the results of an inquiry: he’d asked members to describe their innovations and initiatives in Therapeutic Drug Monitoring and Clinical Toxicology, applied at their respective centres. With the updated IATDMCT website, the Communication’s Committee proposed a space for a regular blog of member interviews to gauge clinical innovations, representing different parts of the world as varied as our members.

The blog started in 2015, and we have had responses from almost all continents. It has been a pleasure to find out (in a less formal manner compared to published research) what members have been up to. It has also been great to hear about different challenges, and how these were overcome. Finally, it has been great to hear various opinions from these leaders on where they think these fields are headed.